Medizinische Universität Graz

STANDARDISED QUALITY OF DIAGNOSTICS AS KEY FACTOR TO IMPROVE QUALITY OF PRIMARY DATA TO MONITOR COVID-19

ERINHA-ADVANCE TNA Project MUG - QIAGEN H2020 Grant Agreement: 824061




The Underestimated Impact of Sample Quality on Data Quality



Report of UN Secretary-general's high-level Panel on Digital Cooperation: *"Gaps in the data on which algorithms are trained can likewise automate existing patterns of discrimination, as machine learning systems are only as good as the data that is fed to them."*


The garbage in and garbage out issue

SARS-CoV-2 RNA stability under various storage conditions - pre-analytical study - workflow













erinha European Research Infrastructure on Highly Pathogenic Agents


Hardt et al., New Biotechology 2022

Saliva collection devices















theoretical spike-in (viral copies)



1



Hardt et al., New Biotechology 2022

ropean Research Infrastructure

Key lessons learned

- Sample collection devices showed marked differences in their sample stabilizing properties
- Some collection devices my lead to false negative SARS-CoV-2 results even within 24 hours transportation, particularly during summer time
- Sample collection devices that inactivate the virus reduce infection risks during sample transport and analysis, and thereby facilitate building diagnostic capacities



The impact of sample pre-analytics on data quality is often underestimated



European Research Infrastructure on Highly Pathogenic Agents

erinha

European Research Infrastructure on Highly Pathogenic Agents Mec Graz

Finland

Poland

Czech Rep.

Slovakia

Romania

Bulgaria

N.Cvpru

Cyprus, J

Germany

ດດື່ມ

Fostering Research to Fight Epidemics

ERINHA is a pan-European distributed research infrastructure dedicated to the study of highconsequence pathogens

- 10 Members throughout Europe
- Provides a coordinated access (CCU) to its member high containment (BSL3+ a BSL4) facilities & expertise
- **Target pathogens** prioritized by the WHO R&D Blueprint requiring a high-containment environment (Ebola, Marburg, Lassa...)
- **Research Scope:** From basic research to preclinical development and testing of MCMs
- Coordinates and is involved in a number of EU and International projects:
 - Outbreak Research





OUNTERAC



Many Thanks to a Great Team







and to our cooperation partner QIAGEN